INO vs. MRNA, AVNS, ZIMV, KIDS, TMCI, CBLL, SMLR, DCTH, BFLY, and RXST
Should you be buying Inovio Pharmaceuticals stock or one of its competitors? The main competitors of Inovio Pharmaceuticals include Moderna (MRNA), AVANOS MEDICAL (AVNS), ZimVie (ZIMV), OrthoPediatrics (KIDS), Treace Medical Concepts (TMCI), CeriBell (CBLL), Semler Scientific (SMLR), Delcath Systems (DCTH), Butterfly Network (BFLY), and RxSight (RXST). These companies are all part of the "medical" sector.
Inovio Pharmaceuticals vs. Its Competitors
Inovio Pharmaceuticals (NASDAQ:INO) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.
Inovio Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -94.31%. Moderna's return on equity of -25.96% beat Inovio Pharmaceuticals' return on equity.
Inovio Pharmaceuticals has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 2.3% of Inovio Pharmaceuticals shares are held by insiders. Comparatively, 11.0% of Moderna shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Moderna had 15 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 18 mentions for Moderna and 3 mentions for Inovio Pharmaceuticals. Moderna's average media sentiment score of 1.03 beat Inovio Pharmaceuticals' score of 0.30 indicating that Moderna is being referred to more favorably in the news media.
Inovio Pharmaceuticals currently has a consensus target price of $8.80, indicating a potential upside of 269.75%. Moderna has a consensus target price of $42.88, indicating a potential upside of 82.40%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than Moderna.
Inovio Pharmaceuticals has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500.
Summary
Moderna beats Inovio Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Inovio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding INO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inovio Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:INO) was last updated on 9/12/2025 by MarketBeat.com Staff
Free INO Stock Alerts